shutterstock_736755118_peter_verreussel

peter verreussel / Shutterstock.com

18 February 2021GeneticsRory O'Neill

Zebrafish start-up secures CRISPR licence

ERS Genomics has agreed to license CRISPR-Cas9 technology to a Barcelona-based start-up which uses a zebrafish-based research model.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Broad Institute presses for CRISPR settlement after EPO revocation

23 January 2020 A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.

Breaking: EPO revokes Broad’s CRISPR patent

16 January 2020 In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

More on this story

Broad Institute presses for CRISPR settlement after EPO revocation

23 January 2020 A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.

Breaking: EPO revokes Broad’s CRISPR patent

16 January 2020 In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

More on this story

Broad Institute presses for CRISPR settlement after EPO revocation

23 January 2020 A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.

Breaking: EPO revokes Broad’s CRISPR patent

16 January 2020 In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB